| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c47ab152647cefce45d8ea0a09b91d0e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3736654583e60531b7fac435ad82c5f2 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2018-00577
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2034-2051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-6852
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2018-00029 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B18-1492
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-062
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C233-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C233-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M25-0127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M25-0012
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C233-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C233-66 |
| filingDate |
2016-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_210a45748a918ea516920eafb714c561
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1678699bfea4534081b0df54dae1e29f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf15fa3ffc6b5cd078299cbb72f725ee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79909c85145403efeff8f9b671fe5061 |
| publicationDate |
2018-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3317249-A1 |
| titleOfInvention |
Diabetes and metabolic syndrome treatment with a novel dual modulator of soluble epoxide hydrolase and peroxisome proliferator-activated receptors |
| abstract |
N-benzylbenzamides that act as dual soluble soluble epoxide hydrolase (sEH)/peroxisome proliferator-activated receptor γ (PPARy) modulators and are useful as medications in the treatment of Metabolic Syndrome (MetS) cluster diseases, including diabetes. Methods of making and using the same are further provided. |
| priorityDate |
2015-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |